Immuneering (IMRX) Capital Expenditures (2020 - 2026)
Immuneering (IMRX) reported Capital Expenditures of $27,367 for Q2 2026, compared with $2,116 a year earlier and down 65.8% from the prior quarter.
Powered by 
Analysis
Immuneering (IMRX) Capital Expenditures (2020 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Immuneering's Capital Expenditures came in at $238,462, up 828.4% year-over-year; for FY2025, it was $142,226, up 67.6% from FY2024.
- Capital Expenditures has a five-year compound annual growth rate of 21.6% (FY2020 to FY2025).
- By year, Capital Expenditures came in at $84,875 in FY2024 (-75.2%), $342,746 in FY2023 (-53.8%), $742,483 in FY2022 and $60,786 in FY2021 (+13.8%).
- Five-year quarterly Capital Expenditures spans a low of $2,116 in Q2 2025 and a high of $393,134 in Q3 2022.
- Year over year, Capital Expenditures gained in two of the last six quarters, with growth averaging 79.4%.
- The high point for year-over-year Capital Expenditures in five years was Q1 2026 (growth of 793.6%); the low point was Q4 2024 (a decline of 94.5%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $79,930 (Q1 2026), $123,910 (Q4 2025) and $7,255 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 1.32 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 322.00 Mn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 893.00 Mn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -321.00 Mn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -763.00 Mn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 513.00 Mn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 140.00 Mn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 533.00 Mn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 112.20 Mn |
| 10 | Immuneering | 269.14 Mn | 269.14 Mn | - | 27,367.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27,367.00 |
| Mar 31, 2026 | 79,930.00 |
| Dec 31, 2025 | 123,910.00 |
| Sep 30, 2025 | 7,255.00 |
| Jun 30, 2025 | 2,116.00 |
| Mar 31, 2025 | 8,945.00 |
| Dec 31, 2024 | 9,356.00 |
| Sep 30, 2024 | 5,268.00 |
| Jun 30, 2024 | 32,773.00 |
| Mar 31, 2024 | 37,478.00 |
| Dec 31, 2023 | 170,918.00 |
| Sep 30, 2023 | 57,149.00 |
| Jun 30, 2023 | 86,686.00 |
| Mar 31, 2023 | 27,993.00 |
| Dec 31, 2022 | 69,302.00 |
| Sep 30, 2022 | 393,134.00 |
| Jun 30, 2022 | 164,997.00 |
| Mar 31, 2022 | 115,050.00 |
| Dec 31, 2021 | 13,052.00 |
| Sep 30, 2021 | 11,346.00 |
API Access
Immuneering Capital Expenditures API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=capital-expenditures&ticker=IMRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "capital-expenditures", "ticker": "IMRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=capital-expenditures&ticker=IMRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();